Skin / tissue repair
GHK-Cu vs BPC-157
GHK-Cu has route-specific topical human evidence; BPC-157 evidence is overwhelmingly preclinical. Do not merge topical and injectable claims.
At a glance
GHK-Cu
BPC-157
Human evidence
Human evidence is route-specific and mixed. A randomized venous-ulcer study of topical 0.4% copper-tripeptide cream found no superiority over vehicle, and a 13-person randomized post-CO2-laser study found no significant objective skin benefit, although subjective satisfaction favored treatment. Injectable/systemic evidence remains much weaker.
Human evidence remains extremely limited. A 2025 systematic review found 35 preclinical studies and only one clinical study; a later retrospective real-world preprint cannot establish efficacy. GI and injury-healing claims remain dominated by animal/preclinical research.
Research focus
Skin, wound healing, collagen, hair/cosmetic research
Musculoskeletal injury, gastrointestinal and wound-healing research
Regulatory status
Injectable GHK-Cu is not an FDA-approved therapeutic product; FDA highlights compounded-injection safety uncertainty.
Not FDA-approved; FDA has highlighted safety-information gaps for compounded BPC-157.
Route / formulation
Topical cosmetic evidence cannot be automatically extrapolated to injected GHK-Cu.
Results from animal models cannot be presented as proven human healing effects. Research-grade product quality varies.
No head-to-head human trial identified GHK-Cu has route-specific topical human evidence; BPC-157 evidence is overwhelmingly preclinical. Do not merge topical and injectable claims.